11th May 2018 07:56
LONDON (Alliance News) - AstraZeneca PLC said Friday that a drug trial for treating chronic obstructive pulmonary disease did not meet its primary end-point.
The pharmaceutical company said the Galathea Phase III trial for Fasenra did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary disease, which causes obstruction of airflow in lungs.
AstraZeneca intends to await results of a separate Fasenra trial called Terranova to determine next steps for Fasenra in COPD. The Galathea trial results do not impact the approved indication of Fasenra in severe eosinophilic asthma.
The safety and tolerability findings in Galathea were consistent with those observed in previous trials with Fasenra. The company is currently conducting a full evaluation of the trial data.
Related Shares:
Astrazeneca